ChemLex
AI-for-science company founded in January 2022 that pairs a proprietary AI-for-chemistry platform with high-throughput automated synthesis; it established its global headquarters and a 24/7 self-driving laboratory in Singapore in December 2025 on the back of a $45M round, running autonomous synthesis services for pharmaceutical and biotech R&D.
Headquarters
Singapore
Year Founded
2022
Founders
Sen (Sean) Lin (founder and CEO)
Country
Singapore
Financial Information
Funding Stage
Venture round (USD 45M, Dec 2025)
Recent Funding
$45M
Funding By
Granite Asia
Core Technology
AI-for-chemistry models integrated with autonomous high-throughput synthesis
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Pharmaceutical partners (undisclosed); MOU with Singapore's EDDC
Academic / Hospital Tie-ups
Experimental Drug Development Centre (EDDC), Singapore
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
24/7 autonomous experimentation that shortens synthesis turnaround and lowers cost for discovery customers